Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New progestins--clinical experiences: gestodene

D Shoupe1

  • 1Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles.

American Journal of Obstetrics and Gynecology
|May 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hormone replacement therapy: consensus and controversies.

Panminerva medica·2014
Same author

Individualizing hormone-therapy according to cardiovascular risk.

Minerva ginecologica·2013
Same author

Individualizing hormone-therapy according to cardiovascular risk.

Minerva medica·2012
Same author

Comparison of estrogen and androgen levels after oral estrogen replacement therapy.

The Journal of reproductive medicine·2002
Same author

Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial.

Annals of internal medicine·2001
Same author

Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.

Fertility and sterility·2001
Same journal

Association of Surgical Approach with Oncologic Outcomes in Low-Risk Cervical Cancer.

American journal of obstetrics and gynecology·2026
Same journal

Trends in Infertility Treatments by Race, Ethnicity, Socioeconomic Status, and Region in U.S. Birth Certificates from Live Births: 2011-2022.

American journal of obstetrics and gynecology·2026
Same journal

Likelihood ratios enhance clinical interpretation of metagenomic prediction of early-onset neonatal sepsis in preterm premature rupture of membranes (Letter-to-the-Editor).

American journal of obstetrics and gynecology·2026
Same journal

Taking risk stratification in preterm premature rupture of membranes to the bedside (Reply to Letter-to-the-Editor).

American journal of obstetrics and gynecology·2026
Same journal

Gestational Age at Full-Term Delivery and Long-Term Offspring Morbidity in Low-Risk Pregnancies: A Population-Based Cohort Study.

American journal of obstetrics and gynecology·2026
Same journal

Trajectories of childbirth-related posttraumatic stress symptoms after a vaginal delivery: a multicenter prospective study.

American journal of obstetrics and gynecology·2026
See all related articles

Gestodene is a potent progestin in oral contraceptives with low side effects and comparable efficacy to existing options. It shows potential benefits for hypertensive patients due to its aldosterone-inhibiting properties.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Reproductive Health

Background:

  • Gestodene is a novel gonane progestin with high progestational potency and minimal estrogenic activity.
  • It exhibits lower androgenic activity compared to older progestins used in oral contraceptives.
  • Gestodene's interaction with mineralocorticoid receptors suggests potential benefits for hypertension.

Purpose of the Study:

  • To evaluate the efficacy and safety of gestodene-containing oral contraceptives.
  • To compare gestodene's profile with existing oral contraceptive formulations.
  • To assess potential therapeutic applications beyond contraception.

Main Methods:

  • In vivo animal studies to assess androgenic activity.
  • Numerous large clinical trials evaluating contraceptive efficacy.

Related Experiment Videos

  • Analysis of side effect profiles, bleeding patterns, and metabolic impacts.

    • Main Results:

    • Gestodene demonstrates high progestational potency and low estrogenic/androgenic activity.
    • Combination with ethinyl estradiol shows comparable pregnancy prevention rates to other oral contraceptives.
    • Low incidence of side effects, minimal impact on lipid/carbohydrate metabolism, and acceptable bleeding profiles were observed.

    Conclusions:

    • Gestodene-containing oral contraceptives are effective and well-tolerated.
    • Gestodene offers a favorable safety profile with potential advantages for specific patient populations.
    • Further evaluation and regulatory approval are pending for wider availability.